文献速递肿瘤 PET/CT

镓68(68Ga)标记成纤维细胞活化蛋白抑制剂PET/CT诊断胆道癌的前瞻性临床研究

Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-02-21

前瞻性研究纳入50例受试者,最终评估47例,比较[68Ga]Ga-DOTA-FAPI与[18F]FDG PET/CT对胆道癌的诊断效能。结果显示[68Ga]Ga-DOTA-FAPI在原发灶、淋巴结转移和远处转移的检出率均高于[18F]FDG,原发灶及转移灶摄取更高,且其摄取与FAP表达、CEA、PLT相关,代谢肿瘤体积与CA199相关。

要点

  • [68Ga]Ga-DOTA-FAPI对胆道癌原发灶检出率97.62%,高于[18F]FDG的85.71%。
  • [68Ga]Ga-DOTA-FAPI对远处转移检出率100%,高于[18F]FDG的83.67%。
  • [68Ga]Ga-DOTA-FAPI摄取与原发灶FAP表达、CEA、PLT及MTV与CA199相关。

核心结论

  • [68Ga]Ga-DOTA-FAPI在胆道癌原发灶和转移灶诊断中摄取和灵敏度高于[18F]FDG。
  • [68Ga]Ga-DOTA-FAPI PET/CT指标与FAP表达、CEA、PLT、CA199之间的相关性得到确认。

研究设计与样本

  • 前瞻性研究(NCT05264688),于2022年1月至2022年7月进行。
  • 50例受试者接受[68Ga]Ga-DOTA-FAPI和[18F]FDG PET/CT扫描并获取病理组织,最终47例纳入评估(平均年龄59.09±10.98岁,范围33-80岁)。
  • 采用Wilcoxon符号秩检验比较两种示踪剂摄取,McNemar检验比较诊断效能,Spearman或Pearson相关分析评估[68Ga]Ga-DOTA-FAPI PET/CT与临床指标的关系。

主要发现

  • [68Ga]Ga-DOTA-FAPI检出率高于[18F]FDG:原发肿瘤97.62% vs 85.71%,淋巴结转移90.05% vs 87.06%,远处转移100% vs 83.67%。
  • 原发灶摄取[68Ga]Ga-DOTA-FAPI高于[18F]FDG:肝内胆管癌18.95±7.47 vs 11.86±0.70(p=0.001);肝外胆管癌14.57±6.16 vs 8.80±4.74(p=0.004)。
  • 腹部和盆腔淋巴结转移摄取[68Ga]Ga-DOTA-FAPI高于[18F]FDG:6.91±6.56 vs 3.94±2.83(p<0.001)。
  • 远处转移摄取[68Ga]Ga-DOTA-FAPI高于[18F]FDG:胸膜、腹膜、大网膜和肠系膜6.37±4.21 vs 4.50±1.96(p=0.01);骨12.15±6.43 vs 7.51±4.54(p=0.008)。
  • [68Ga]Ga-DOTA-FAPI摄取与FAP表达(Spearman r=0.432,p=0.009)、CEA(Pearson r=0.364,p=0.012)、PLT(Pearson r=0.35,p=0.016)显著相关;代谢肿瘤体积与CA199(Pearson r=0.436,p=0.002)显著相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study is to investigate the [68Ga]Ga-DOTA-FAPI PET/CT diagnosis performance in biliary tract carcinoma (BTC) and analyze the association between [68Ga]Ga-DOTA-FAPI PET/CT and clinical indexes. METHODS: A prospective study (NCT05264688) was performed between January 2022 and July 2022. Fifty participants were scanned using [68Ga]Ga-DOTA-FAPI and [18F]FDG PET/CT and acquired pathological tissue. We employed the Wilcoxon signed-rank test to compare the uptake of [68Ga]Ga-DOTA-FAPI and [18F]FDG, and the McNemar test was used to compare the diagnostic efficacy between the two tracers. Spearman or Pearson correlation was used to assess the association between [68 Ga]Ga-DOTA-FAPI PET/CT and clinical indexes. RESULTS: In total, 47 participants (mean age 59.09 ± 10.98 [range 33-80 years]) were evaluated. The [68Ga]Ga-DOTA-FAPI detection rate was greater than [18F]FDG in primary tumors (97.62% vs. 85.71%), nodal metastases (90.05% vs. 87.06%), and distant metastases (100% vs. 83.67%). The uptake of [68Ga]Ga-DOTA-FAPI was higher than [18F]FDG in primary lesions (intrahepatic cholangiocarcinoma, 18.95 ± 7.47 vs. 11.86 ± 0.70, p = 0.001; extrahepatic cholangiocarcinoma, 14.57 ± 6.16 vs. 8.80 ± 4.74, p = 0.004), abdomen and pelvic cavity nodal metastases (6.91 ± 6.56 vs. 3.94 ± 2.83, p < 0.001), and distant metastases (pleural, peritoneum, omentum, and mesentery, 6.37 ± 4.21 vs. 4.50 ± 1.96, p = 0.01; bone, 12.15 ± 6.43 vs. 7.51 ± 4.54, p = 0.008). There was a significant correlation between [68Ga]Ga-DOTA-FAPI uptake and fibroblast-activation protein (FAP) expression (Spearman r = 0.432, p = 0.009), carcinoembryonic antigen (CEA) (Pearson r = 0.364, p = 0.012), and platelet (PLT) (Pearson r = 0.35, p = 0.016). Meanwhile, a significant relationship between [68Ga]Ga-DOTA-FAPI metabolic tumor volume and carbohydrate antigen199 (CA199) (Pearson r = 0.436, p = 0.002) was confirmed. CONCLUSION: [68Ga]Ga-DOTA-FAPI had a higher uptake and sensitivity than [18F]FDG in the diagnosis of BTC primary and metastatic lesions. The correlation between [68Ga]Ga-DOTA-FAPI PET/CT indexes and FAP expression, CEA, PLT, and CA199 were confirmed. TRIAL REGISTRATION: clinicaltrials.gov: NCT 05,264,688.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jinghua L, Kui X, Deliang G, et al. Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 36809426. doi:10.1007/s00259-023-06137-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。